Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04856046 · ClinicalTrials.gov registry record
Detection of Plasma DNA Methylation in Peripheral Blood From Patients With Resectable Liver Cancer
A clinical trial of Resectable Hepatocellular Carcinoma, sponsored by Mayo Clinic.
- Active
- Registry status
- 36
- Enrollment target
- 1
- Study location
NCT04856046 is a study of Resectable Hepatocellular Carcinoma that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 36 participants, below the 42-participant average among 4 other Resectable Hepatocellular Carcinoma trials with a reported enrollment target (14% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04856046, a study of Resectable Hepatocellular Carcinoma, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This study explores the potential values of a new blood test approach to detect measurable residual disease or early coming back of cancer (recurrence)/cancer growing, spreading, or getting worse (progression) in patients with liver cancer that can be removed by surgery (resectable). The development of novel cancer biomarkers for liver cancer may help in clinical decision making and lead to improvements in patient outcomes by facilitating prediction of the response to specific treatments, improved monitoring of patients on treatment, and better prognostication of patient outcomes, thus improving stratification for clinical trials.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Electronic Health Record Review
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2021-11-06 |
| Est. Completion | 2026-04-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04856046
The ClinicalTrials.gov registry entry for NCT04856046 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 42-participant average among 4 other Resectable Hepatocellular Carcinoma trials with a reported enrollment target (14% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Resectable Hepatocellular Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Biospecimen Collection is the first listed.
NCT04856046 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT04856046 about?
NCT04856046 is a clinical study titled "Detection of Plasma DNA Methylation in Peripheral Blood From Patients With Resectable Liver Cancer". This study explores the potential values of a new blood test approach to detect measurable residual disease or early coming back of cancer (recurrence)/cancer growing, spreading, or getting worse (progression) in patients with liver cancer that can be removed by surgery (resectable). The development...
What is the current status of trial NCT04856046?
This trial is currently active not recruiting. The enrollment target is 36 participants. The study started on 2021-11-06. Estimated completion is 2026-04-01.
What conditions does trial NCT04856046 study?
This clinical trial studies the following conditions: Resectable Hepatocellular Carcinoma.
What interventions are being tested in trial NCT04856046?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Electronic Health Record Review (OTHER).
Who is sponsoring clinical trial NCT04856046?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04856046 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Resectable Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SIRT With Tremelimumab and Durvalumab for Resectable HCC
RECRUITING · Phase 1
-
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
RECRUITING · Phase 1
-
Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer
ACTIVE NOT RECRUITING · Phase 2
-
SBRT + Atezolizumab + Bevacizumab in Resectable HCC
ACTIVE NOT RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.